We thought Actavis had a love triangle going with potential merger partners Warner Chilcott and Valeant Pharmaceuticals, as an analyst dubbed it earlier this week. Now, news emerges that it's more like a love quadrangle, with rejections on two sides.
Valeant Pharmaceuticals and Actavis are getting downright buddy-buddy. Less than a week after partnering up on three skin products, the two companies have wrapped up a patent fight over two others. The settlement sets launch dates for both copycat versions, and gives Valeant a share in the proceeds.
Mylan has had an on-again, off-again relationship with the former Dey plant in Napa County, CA. The plan to close it is back on and by year's end the lights will be off.
The way Valeant Pharmaceuticals CEO J. Michael Pearson keeps flashing around cash and making deals, you would think nothing could dampen the outlook for the rapidly expanding drug operation. But like its peers, it can be undermined by a well targeted generic.
As shortages of sterile injectables persist, the makeup of that part of the industry is in flux. Now that Mylan has agreed to buy Agila Specialties, the injectables unit of Strides Arcolab, for $1.6 billion, analysts think Claris Lifesciences could be next.
Now that Mylan has agreed to buy Strides Arcolab's injectables unit for $1.6 billion, analysts are seeing potential injectable drug deals on every corner.
Jordan-based Hikma has become the second largest player in the U.S. sterile injectables market by riding a wave of manufacturing woes that has washed over competitors. And while it struggles with problems at its own tablet manufacturing plant, its injectables business keeps on growing as competitors like Hospira continue to struggle.
There was lots of talk about who was eyeing the injectables business of Strides Arcolab before Mylan snatched the prize. And just in case some of those left behind are hanging their heads in disappointment, drugmaker Hikma Pharmaceuticals wants them to know it has an injectables business that it might be willing to part with.
Manufacturing problems with sterile injectables at Hospira ($HSP), Ben Venue and elsewhere have exacerbated drug shortages over the last few years, while giving an opening to smaller players that can flll in the gaps.
Score another deal for Mylan as it methodically expands its manufacturing capabilities in India.